arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BIOADAPTIVES, INC.

BDPT

— Price unavailable

10 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

BIOADAPTIVES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth 44.3% ↗

Op. Margin —

ROIC 48.9% ↗

FCF / Share None

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$18.28K

↑ +44.3% —

Net Income Profit after all expenses

$-1.56M

↓ -73.3% —

FCF / Share Free cash flow per share

$-0.04

↓ -676.4% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	44.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+453%)	-55.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-796%)	66.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+729%)	-13.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-264%)	21.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+164%)	64.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+704%)	—	—	—	—
Net Income Growth YoY (%)	-73.3% Weak ↓ Weak Declining Year-over-year change in net income	-26.2% Weak ↓ Weak Declining Year-over-year change in net income	20.4% Good ↑ Good Improving Year-over-year change in net income	14.7% Fair ↑ Fair Improving Year-over-year change in net income	-23.9% Weak ↑ Weak Improving Year-over-year change in net income	-254.6% Weak ↓ Weak Declining Year-over-year change in net income	83.0% Excellent Excellent Year-over-year change in net income	45.4% Excellent Excellent Year-over-year change in net income	—	—
Revenue CAGR 3Y (%)	2.1% Caution ↓ Caution Declining Compound annual revenue growth over 3 years	-13.8% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	20.5% Excellent Excellent Compound annual revenue growth over 3 years	20.0% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	2.3% Caution Caution Compound annual revenue growth over 5 years	5.0% Fair Fair Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.34x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.28x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.31x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.25x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.15x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.30x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.02x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	48.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	41.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	11.0% Good Good Return earned on debt + equity capital invested Optimal: > 10%	23.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	1645107.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-461.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-229.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-220.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-1130.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	-3443.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	73.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+388%)	61.4% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+309%)	43.3% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+188%)	61.7% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+311%)	96.1% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+540%)	61.4% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+310%)	28.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+90%)	202.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1252%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Interest Coverage (x)	-14.70x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-6.55x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1.41x Weak Weak Operating income divided by interest expense Optimal: > 5x	-1.46x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-215.21K	$-261.88K	$-88.56K	$-82.94K	$-82.94K	$-4.59K	$-12.31K	—	$-37.87K	$-18.61K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	—	—	$0.00	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	—	—	$-0.12	—	—	—	—	—	$-0.21	—
Free Cash Flow per Share (USD)	—	—	$-0.04	—	—	—	—	—	$-0.00	—
Book Value per Share (USD)	$-0.18	$-0.18	$-0.28	$-0.01	$-0.02	$-0.06	$-0.05	$-0.04	$-0.00	$0.01
Tangible Book Value per Share (USD)	$-0.18	$-0.18	$-0.28	$-0.01	$-0.02	$-0.06	$-0.05	$-0.04	$-0.00	$0.01
Basic Weighted Avg Shares (shares)	—	—	5.97M	—	—	—	—	—	12.47M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Working Capital (USD)	$-2.14M	$-1.46M	$-1.66M	$-1.45M	$-1.15M	$-1.38M	$-839.88K	$-605.93K	$-1.17K	$88.47K
Total Equity (USD)	$-2.13M	$-1.46M	$-1.65M	$-1.45M	$-1.09M	$-1.38M	$-839.88K	$-693.74K	$-117.00	$88.47K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2014 10-K ↗	FY 2016 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$18.28K	$12.67K	$28.57K	$17.18K	$19.78K	$16.33K	$9.93K	—	—	—
Depreciation Expense (USD)	$4.00K	$0.00	—	—	—	—	—	—	$527.00	—
Net Income, GAAP (USD)	$-1.56M	$-899.16K	$-712.47K	$-895.57K	$-1.05M	$-847.24K	$-238.93K	$-1.41M	$-2.58M	—
Operating Cash Flow (USD)	$-516.02K	$-249.52K	$-223.77K	$-227.26K	$-158.65K	$-106.89K	$-168.12K	$-420.14K	$-58.63K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 40 quarters

BIOADAPTIVES, INC.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BDPT with peers